論文 - 詳細
| RRC ID | 19667 |
|---|---|
| 著者 | Moreno JL, Holloway T, Rayannavar V, Sealfon SC, González-Maeso J. |
| タイトル | Chronic treatment with LY341495 decreases 5-HT(2A) receptor binding and hallucinogenic effects of LSD in mice. |
| ジャーナル | Neurosci Lett |
| Abstract |
Hallucinogenic drugs, such as lysergic acid diethylamide (LSD), mescaline and psilocybin, alter perception and cognitive processes. All hallucinogenic drugs have in common a high affinity for the serotonin 5-HT(2A) receptor. Metabotropic glutamate 2/3 (mGlu2/3) receptor ligands show efficacy in modulating the cellular and behavioral responses induced by hallucinogenic drugs. Here, we explored the effect of chronic treatment with the mGlu2/3 receptor antagonist 2S-2-amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl)-propionic acid (LY341495) on the hallucinogenic-like effects induced by LSD (0.24mg/kg). Mice were chronically (21 days) treated with LY341495 (1.5mg/kg), or vehicle, and experiments were carried out one day after the last injection. Chronic treatment with LY341495 down-regulated [(3)H]ketanserin binding in somatosensory cortex of wild-type, but not mGlu2 knockout (KO), mice. Head-twitch behavior, and expression of c-fos, egr-1 and egr-2, which are responses induced by hallucinogenic 5-HT(2A) agonists, were found to be significantly decreased by chronic treatment with LY341495. These findings suggest that repeated blockade of the mGlu2 receptor by LY341495 results in reduced 5-HT(2A) receptor-dependent hallucinogenic effects of LSD. |
| 巻・号 | 536 |
| ページ | 69-73 |
| 公開日 | 2013-3-1 |
| DOI | 10.1016/j.neulet.2012.12.053 |
| PII | S0304-3940(13)00013-X |
| PMID | 23333599 |
| PMC | PMC3578056 |
| MeSH | Amino Acids / pharmacology* Animals Drug Antagonism Early Growth Response Protein 1 / metabolism Early Growth Response Protein 2 / metabolism Hallucinogens / metabolism Hallucinogens / pharmacology* Lysergic Acid Diethylamide / metabolism Lysergic Acid Diethylamide / pharmacology* Male Mice Mice, Knockout Proto-Oncogene Proteins c-fos / metabolism Radioligand Assay Receptor, Serotonin, 5-HT2A / metabolism* Receptors, Metabotropic Glutamate / antagonists & inhibitors* Receptors, Metabotropic Glutamate / genetics Receptors, Metabotropic Glutamate / metabolism Somatosensory Cortex / metabolism Stereotyped Behavior / drug effects Xanthenes / pharmacology* |
| IF | 2.274 |
| 引用数 | 23 |
| WOS 分野 | NEUROSCIENCES |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 7 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 3.0 |
| リソース情報 | |
| 実験動物マウス | RBRC01351 |